Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Vaxcyte, Inc.
  6. News
  7. Summary
    PCVX   US92243G1085

VAXCYTE, INC.

(PCVX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Vaxcyte : to Present at Guggenheim 2nd Annual Vaccine and Infectious Disease Conference

09/28/2021 | 04:05pm EST

FOSTER CITY, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that Company management will participate in a fireside chat at the Guggenheim 2nd Annual Vaccine and Infectious Disease Conference on Tuesday, October 5, 2021 at 11:30am ET.

A live webcast of the presentation can be accessed through the Investors & Media section of the Company’s website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference.

About Vaxcyte
Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCF™ platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. Vaxcyte’s lead vaccine candidate, VAX-24, is a preclinical, 24-valent broad-spectrum pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease. Vaxcyte’s pipeline also includes VAX-XP, a PCV with an expanded breadth of coverage of at least 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease by targeting the keystone pathogen responsible for this chronic, oral inflammatory disease. For more information, visit www.vaxcyte.com.

Contacts:
Andrew Guggenhime, President and Chief Financial Officer
Vaxcyte, Inc.
650-837-0111
investors@vaxcyte.com

Janet Graesser, Vice President, Corporate Communications and Investor Relations
Vaxcyte, Inc.
917-685-8799
media@vaxcyte.com 


Primary Logo

Source: Vaxcyte, Inc.

2021 GlobeNewswire, Inc., source Press Releases

All news about VAXCYTE, INC.
11/11Vaxcyte to Present at Upcoming Investor Conferences
GL
11/10Vaxcyte Investor Presentation November 2021
PU
11/10Vaxcyte Reports Third Quarter 2021 Financial Results and Provides Business Update - For..
PU
11/10Vaxcyte Reports Third Quarter 2021 Financial Results and Provides Business Update
GL
11/10VAXCYTE, INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
11/10Vaxcyte, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
10/28VAXCYTE, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
10/28Vaxcyte Appoints Carlos Paya and Michael Kamarck to Its Board of Directors
AQ
10/28Vaxcyte, Inc. Announces Board Changes
CI
10/22INSIDER SELL : Vaxcyte
MT
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -101 M - -
Net Debt 2021 - - -
P/E ratio 2021 -10,2x
Yield 2021 -
Capitalization 1 048 M 1 048 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 1 048x
Nbr of Employees 58
Free-Float 84,3%
Chart VAXCYTE, INC.
Duration : Period :
Vaxcyte, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VAXCYTE, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 19,86 $
Average target price 50,50 $
Spread / Average Target 154%
EPS Revisions
Managers and Directors
Grant E. Pickering Chief Executive Officer & Director
Andrew L. Guggenhime President & Chief Financial Officer
Carlos V. Paya Chairman
Romulo Colindres Chief Medical Officer
Jim Wassil Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
VAXCYTE, INC.-25.25%1 048
GILEAD SCIENCES, INC.20.61%88 146
BIONTECH SE326.89%84 049
REGENERON PHARMACEUTICALS33.17%67 266
WUXI APPTEC CO., LTD.24.40%64 416
VERTEX PHARMACEUTICALS-22.32%46 678